Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
4 medications & technologies that could transform cardiology in 2022 | Electrophysiologists debut new tech
Tuesday, February 22, 2022
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Today's News and Trends

4 new medications and technologies that could transform cardiology in 2022

The FDA has already approved one of the medications, with a decision on another expected by the end of April. 

READ MORE >
The LDL-lowering medication inclisiran (Leqvio) was recently cleared by the FDA. It used only two doses per year. It was included it the Cleveland Clinic annual list of the top 10 medical innovations expected to make a big impact on patient care in 2022.
Share on Twitter Share on Facebook Share on Linkedin

4 new medications and technologies that could transform cardiology in 2022

Share on Twitter Share on Facebook Share on Linkedin
The LDL-lowering medication inclisiran (Leqvio) was recently cleared by the FDA. It used only two doses per year. It was included it the Cleveland Clinic annual list of the top 10 medical innovations expected to make a big impact on patient care in 2022.
The FDA has already approved one of the medications, with a decision on another expected by the end of April. 
READ MORE >

FDA expands two Medtronic cardiac cryoablation catheters for AVNRT

The two single-use devices are now approved for the treatment of pediatric AVNRT.

READ MORE >
The FDA has cleared Medtronic's Freezor and Freezor Xtra cardiac cryoablation catheters for the treatment of pediatric atrioventricular nodal reentrant tachycardia (AVNRT).
Share on Twitter Share on Facebook Share on Linkedin

FDA expands two Medtronic cardiac cryoablation catheters for AVNRT

Share on Twitter Share on Facebook Share on Linkedin
The FDA has cleared Medtronic's Freezor and Freezor Xtra cardiac cryoablation catheters for the treatment of pediatric atrioventricular nodal reentrant tachycardia (AVNRT).
The two single-use devices are now approved for the treatment of pediatric AVNRT.
READ MORE >

Electrophysiologists debut new technology that builds interactive cardiac maps out of 12-lead ECGs

The solution, which gained FDA clearance in November 2021, is now being used by specialists at the University of California San Diego Health.

READ MORE >
The Vektor Medical vMap system takes standard 12-lead ECGs and converts them into detailed electro anatomical maps for us in catheter ablation procedures.
Share on Twitter Share on Facebook Share on Linkedin

Electrophysiologists debut new technology that builds interactive cardiac maps out of 12-lead ECGs

Share on Twitter Share on Facebook Share on Linkedin
The Vektor Medical vMap system takes standard 12-lead ECGs and converts them into detailed electro anatomical maps for us in catheter ablation procedures.
The solution, which gained FDA clearance in November 2021, is now being used by specialists at the University of California San Diego Health.
READ MORE >

Featured Articles

Cardiac MRI a powerful tool for predicting sudden cardiac death, arrhythmia after CIED implantation

The study's authors suspect their findings could improve patient selection for CIEDs. 

READ MORE >
A new artificial intelligence tool can detect heart disease on cardiovascular MRI scans in seconds with equal or superior precision as clinicians. 
Share on Twitter Share on Facebook Share on Linkedin

Cardiac MRI a powerful tool for predicting sudden cardiac death, arrhythmia after CIED implantation

Share on Twitter Share on Facebook Share on Linkedin
A new artificial intelligence tool can detect heart disease on cardiovascular MRI scans in seconds with equal or superior precision as clinicians. 
The study's authors suspect their findings could improve patient selection for CIEDs. 
READ MORE >

Unreliable? 76% of world’s blood pressure monitors have not been validated

Researchers examined data on more than 3,400 BP devices used all over the world. A significant majority of them were never clinically validated for accuracy. 

READ MORE >
questions.jpg
Share on Twitter Share on Facebook Share on Linkedin

Unreliable? 76% of world’s blood pressure monitors have not been validated

Share on Twitter Share on Facebook Share on Linkedin
questions.jpg
Researchers examined data on more than 3,400 BP devices used all over the world. A significant majority of them were never clinically validated for accuracy. 
READ MORE >

In Case You Missed It

Links to the ACC.22 late-breaking clinical trials

Learn more about the late-breaking studies presented at ACC.22 in Washington, D.C. 

READ MORE >
The American College of Cardiology (ACC) annual meeting ACC.22 is the premier source for the latest cardiac science. #ACC22 Here are links to all the late breaking studies, trials and late-breaker science at the annual meeting conference. #ACC2022 #ACC
Share on Twitter Share on Facebook Share on Linkedin

Links to the ACC.22 late-breaking clinical trials

Share on Twitter Share on Facebook Share on Linkedin
The American College of Cardiology (ACC) annual meeting ACC.22 is the premier source for the latest cardiac science. #ACC22 Here are links to all the late breaking studies, trials and late-breaker science at the annual meeting conference. #ACC2022 #ACC
Learn more about the late-breaking studies presented at ACC.22 in Washington, D.C. 
READ MORE >

Continued anticoagulation after primary PCI boosts survival among STEMI patients

A key takeaway from the group's analysis was that the rate of major bleeding events did not significantly change. 

READ MORE >
elderly patient mask covid
Share on Twitter Share on Facebook Share on Linkedin

Continued anticoagulation after primary PCI boosts survival among STEMI patients

Share on Twitter Share on Facebook Share on Linkedin
elderly patient mask covid
A key takeaway from the group's analysis was that the rate of major bleeding events did not significantly change. 
READ MORE >

In Other News

95% of doctors believe COVID-19 has exposed cracks in the medicine supply chain

Sixty-two percent of those surveyed believe significant reliance on other countries for medicines is among the biggest contributing factor to medicine shortages, according to new survey results.

READ MORE >
pills-medicine-rx.jpg
Share on Twitter Share on Facebook Share on Linkedin

95% of doctors believe COVID-19 has exposed cracks in the medicine supply chain

Share on Twitter Share on Facebook Share on Linkedin
pills-medicine-rx.jpg
Sixty-two percent of those surveyed believe significant reliance on other countries for medicines is among the biggest contributing factor to medicine shortages, according to new survey results.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Safety concerns lead to new recall | FDA approves surgical device | Parents in jail after obese son's death | A fraud warning
AI making an impact behind the scenes | New EARLY TAVR data | Americans keep poisoning themselves with semaglutide
Week in Review: TAVR vs. SAVR | FDA clears AI tech | Payment model confusion | Private equity & cardiology | Injuries after PCI
Heart surgery kits recalled | Sex-specific outcomes after TAVR & SAVR | A new risk calculator | FDA clears tricuspid valve
Thousands of heart surgery kits recalled | TAVR for AR linked to 'encouraging' data | Carotid IVL | Progress for new HCM drug
AI company founded by cardiologist makes big splash | Getting clinicians on the same page | Kidney injuries after PCI
Sweeping TAVR changes on the way | Pushing back against AI-powered prior authorization | FDA highlights recall after injuries

Pagination

    • Current page 1
    • Page 2
    • Page 3
    • Page 4
    • Page 5
    • Page 6
    • Page 7
    • Page 8
    • Page 9 …
    • Next page ››
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme